Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ocular Therapeutix Inc. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, indicating that the company's active patent matters involve at least two different specialized fields within biotechnology. This split requires the prosecution team to manage different sets of examiner expectations and technical guidelines.
The portfolio is being reviewed by 3 distinct examiners. BASQUILL, SEAN M is the busiest examiner, currently overseeing 2 pending office actions. This concentration with BASQUILL, SEAN M means that half of the company's 4 pending office actions are under the authority of a single individual, making his examination style particularly influential for the portfolio's immediate success.
With 3 distinct examiners handling the 4 pending office actions, the workload is not perfectly even. While BASQUILL, SEAN M manages 2 pending office actions, the remaining two actions are split among the other examiners. This arrangement in the Biotechnology & Pharmaceuticals sector highlights a mix of concentrated and distributed prosecution efforts across the 2 distinct art units involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BASQUILL, SEAN M | 2 | 38.8% | +21.7% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| BERRIOS, JENNIFER A | 1 | 37.0% | +49.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19562371 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | AZPURU, CARLOS A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17549307 | OCULAR INSERT CONTAINING A GLUCOCORTICOID | BERRIOS, JENNIFER A | 3d overdue |
| 18706306 | PRODRUGS OF AXITINIB | VALLE, ERNESTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17549307 | OCULAR INSERT CONTAINING A GLUCOCORTICOID | BERRIOS, JENNIFER A | 3d overdue |
| 19562371 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | AZPURU, CARLOS A | — |
| 18824391 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | BASQUILL, SEAN M | — |
| 18726302 | INTRACANALICULAR INSERT COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | BASQUILL, SEAN M | — |
| 18706306 | PRODRUGS OF AXITINIB | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1614 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19562371 | OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR | AZPURU, CARLOS A | 1617 | §103Other | Non-Final OA | — | Pending | Mar 10, 2026 |
| 18824391 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | BASQUILL, SEAN M | — | §103DP | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18726302 | INTRACANALICULAR INSERT COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | BASQUILL, SEAN M | 1614 | §103§112DP | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18706306 | PRODRUGS OF AXITINIB | VALLE, ERNESTO | — | §102§103§112 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 17549307 | OCULAR INSERT CONTAINING A GLUCOCORTICOID | BERRIOS, JENNIFER A | 1613 | §103§112 | Final Rejection | 3d overdue | Pending | Dec 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial